Answers are grounded in this paper and cite their sources.
Objectives The need for agents that can modify the progression of Parkinson’s disease necessitates a search for drugs with a disease-modifying property. Thus, we investigated the neuroprotective effect of canagliflozin (CANA), on rotenone (ROT)-induced Parkinsonism in mice. Methods Thirty-six male Swiss mice (n = 6) were randomly divided into six groups and treated by oral gavage as follows: vehicle (0.5%v/v chloroform + carboxymethylcellulose in 0.9% saline) 10 ml/kg, vehicle + ROT (1 mg/kg), CANA (25, 50, and 100 mg/kg) + ROT, and CANA (100 mg/kg) for 21 consecutive days. Behavioural assays were conducted on Day 21. The animals were thereafter euthanized to assess the impact of treatments on oxidative stress, acetylcholinesterase (AChE) activity, dopamine concentration, and catechol-O-methyltransferase (COMT) activity in the midbrain. In addition, in silico studies were performed to evaluate CANA’s interaction with COMT and phosphatidylinositol 3-kinase (PI3K). Key findings CANA (50 and 100 mg/kg) reduced rotenone-induced locomotor deficit evidenced in significant increased number of line crossings (47% and 73%, respectively) and mobility time (64% and 73%, respectively), and shortened immobility time in open field test. CANA significantly prolonged the latency to fall in the rotarod test, and also increased the distance covered but decreased the number of foot slips in the beam walk test. Similarly, CANA significantly reduced rotenone-induced catalepsy and attenuated neuro-oxidative stress and dopamine depletion, and enhanced AChE activity and inhibited COMT. In silico studies revealed favourable interactions of CANA with COMT and PI3K. Conclusions CANA mitigated rotenone-induced parkinsonism, oxidative stress, and dopamine depletion by modulating COMT and AChE.
No takes yet. Share an insight, caveat, or question.
Irokosu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: